Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660

Article  PubMed  CAS  Google Scholar 

Preisser F, Cooperberg MR, Crook J, Feng F, Graefen M, Karakiewicz PI et al (2020) Intermediate-risk prostate cancer: stratification and management. Eur Urol Oncol 3:270–280. https://doi.org/10.1016/j.euo.2020.03.002

Article  PubMed  Google Scholar 

Lalonde E, Ishkanian AS, Sykes J, Fraser M, Ross-Adams H, Erho N et al (2014) Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. Lancet Oncol 15:1521–1532. https://doi.org/10.1016/S1470-2045(14)71021-6

Article  PubMed  Google Scholar 

Fazekas T, Shim SR, Basile G, Baboudjian M, Kói T, Przydacz M et al (2024) Magnetic resonance imaging in prostate cancer screening. JAMA Oncol 10:745. https://doi.org/10.1001/jamaoncol.2024.0734

Article  PubMed  PubMed Central  Google Scholar 

Diamand R, Peltier A, Roche J, Lievore E, Lacetera V, Chiacchio G et al (2023) Risk stratification for early biochemical recurrence of prostate cancer in the era of multiparametric magnetic resonance imagining-targeted biopsy. Prostate 83:572–579. https://doi.org/10.1002/pros.24490

Article  PubMed  Google Scholar 

Diamand R, Albisinni S, Roche J-B, Lievore E, Lacetera V, Chiacchio G et al (2023) Expanding active surveillance criteria for Low- and Intermediate-risk prostate cancer: can we accurately predict the risk of misclassification for patients diagnosed by multiparametric magnetic resonance Imaging–targeted biopsy?? Eur Urol Focus 9:298–302. https://doi.org/10.1016/j.euf.2022.09.011

Article  PubMed  Google Scholar 

Baboudjian M, Roumiguié M, Peltier A, Oderda M, Barret E, Fromont G et al (2022) Grade group 1 prostate cancer on biopsy: are we still missing aggressive disease in the era of image-directed therapy? World J Urol 40:2423–2429. https://doi.org/10.1007/s00345-022-04130-z

Article  PubMed  Google Scholar 

Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S et al (2011) Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-Deficient prostate cancer. Cancer Cell 19:575–586. https://doi.org/10.1016/j.ccr.2011.04.008

Article  PubMed  PubMed Central  CAS  Google Scholar 

Abate-Shen C, Shen MM (2000) Molecular genetics of prostate cancer. Genes Dev 14:2410–2434. https://doi.org/10.1101/gad.819500

Article  PubMed  CAS  Google Scholar 

Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS et al (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18:11–22. https://doi.org/10.1016/j.ccr.2010.05.026

Article  PubMed  PubMed Central  CAS  Google Scholar 

Pourmand G, Ziaee AA, Abedi AR, Mehrsai A, Alavi HA, Ahmadi A et al (2007) Role of PTEN gene in progression of prostate cancer. Urol J 4(2):95–100.

Wang Y, Dai B (2015) PTEN genomic deletion defines favorable prognostic biomarkers in localized prostate cancer: a systematic review and meta-analysis. Int J Clin Exp Med 8(4):5430–5437.

Gandaglia G, Ploussard G, Valerio M, Mattei A, Fiori C, Fossati N et al (2019) A novel nomogram to identify candidates for extended pelvic lymph node dissection among patients with clinically localized prostate cancer diagnosed with magnetic resonance Imaging-targeted and systematic biopsies. Eur Urol 75. https://doi.org/10.1016/j.eururo.2018.10.012

Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M et al (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 71:618–629. https://doi.org/10.1016/j.eururo.2016.08.003

Article  PubMed  Google Scholar 

Lotan TL, Heumann A, Rico SD, Hicks J, Lecksell K, Koop C et al (2017) PTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort. Oncotarget 8:65566–65576. https://doi.org/10.18632/oncotarget.19217

Article  PubMed  PubMed Central  Google Scholar 

Krohn A, Diedler T, Burkhardt L, Mayer P-S, De Silva C, Meyer-Kornblum M et al (2012) Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG Fusion-Positive and Fusion-Negative prostate cancer. Am J Pathol 181:401–412. https://doi.org/10.1016/j.ajpath.2012.04.026

Article  PubMed  CAS  Google Scholar 

Leinonen KA, Saramäki OR, Furusato B, Kimura T, Takahashi H, Egawa S et al (2013) Loss of PTEN is associated with aggressive behavior in ERG-Positive prostate cancer. Cancer Epidemiol Biomarkers Prev 22:2333–2344. https://doi.org/10.1158/1055-9965.EPI-13-0333-T

Article  PubMed  PubMed Central  CAS  Google Scholar 

Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat J-P et al (2012) Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 44:685–689. https://doi.org/10.1038/ng.2279

Article  PubMed  PubMed Central  CAS  Google Scholar 

Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JMC, Papaemmanuil E et al (2015) The evolutionary history of lethal metastatic prostate cancer. Nature 520:353–357. https://doi.org/10.1038/nature14347

Article  PubMed  PubMed Central  CAS  Google Scholar 

Sircar K, Yoshimoto M, Monzon FA, Koumakpayi IH, Katz RL, Khanna A et al (2009) PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J Pathol 218:505–513. https://doi.org/10.1002/path.2559

Article  PubMed  CAS  Google Scholar 

Ahearn TU, Pettersson A, Ebot EM, Gerke T, Graff RE, Morais CL et al (2015) A prospective investigation of PTEN loss and ERG expression in lethal prostate cancer. J Natl Cancer Inst 108:djv346. https://doi.org/10.1093/jnci/djv346

Article  PubMed  PubMed Central  CAS  Google Scholar 

Lotan TL, Wei W, Morais CL, Hawley ST, Fazli L, Hurtado-Coll A et al (2016) PTEN loss as determined by Clinical-grade immunohistochemistry assay is associated with worse Recurrence-free survival in prostate cancer. Eur Urol Focus 2:180–188. https://doi.org/10.1016/j.euf.2015.07.005

Article  PubMed  PubMed Central  Google Scholar 

Haffner MC, Zwart W, Roudier MP, True LD, Nelson WG, Epstein JI et al (2021) Genomic and phenotypic heterogeneity in prostate cancer. Nat Rev Urol 18:79–92. https://doi.org/10.1038/s41585-020-00400-w

Article  PubMed  Google Scholar 

Erickson AM, Lokman U, Lahdensuo K, Tornberg S, Visapaa H, Bergroth R et al (2020) PTEN and ERG expression in MRI-ultrasound guided fusion biopsy correlated with radical prostatectomy findings in men with prostate cancer. Prostate 80:1118–1127. https://doi.org/10.1002/pros.24040

Article  PubMed  CAS  Google Scholar 

Shah RB, Bentley J, Jeffery Z, DeMarzo AM (2015) Heterogeneity of PTEN and ERG expression in prostate cancer on core needle biopsies: implications for cancer risk stratification and biomarker sampling. Hum Pathol 46:698–706. https://doi.org/10.1016/j.humpath.2015.01.008

Article  PubMed  CAS  Google Scholar 

Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK et al (2017) Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 389:815–822. https://doi.org/10.1016/S0140-6736(16)32401-1

Article  PubMed  Google Scholar 

Gordetsky JB, Thomas JV, Nix JW, Rais-Bahrami S (2017) Higher prostate cancer grade groups are detected in patients undergoing multiparametric MRI-targeted biopsy compared with standard biopsy. Am J Surg Pathol 41:101–105. https://doi.org/10.1097/PAS.0000000000000723

Article  PubMed  Google Scholar 

Baumgartner E, del Carmen Rodriguez Pena M, Eich M-L, Porter KK, Nix JW, Rais-Bahrami S et al (2019) PTEN and ERG detection in multiparametric magnetic resonance imaging/ultrasound fusion targeted prostate biopsy compared to systematic biopsy. Hum Pathol 90:20–26. https://doi.org/10.1016/j.humpath.2019.04.016

Article  PubMed  PubMed Central  Google Scholar 

Eineluoto JT, Sandeman K, Pohjonen J, Sopyllo K, Nordling S, Stürenberg C et al (2021) Associations of PTEN and ERG with magnetic resonance imaging visibility and assessment of Non–organ-confined pathology and biochemical recurrence after radical prostatectomy. Eur Urol Focus 7:1316–1323. https://doi.org/10.1016/j.euf.2020.06.016

Article  PubMed  Google Scholar 

Houlahan KE, Salmasi A, Sadun TY, Pooli A, Felker ER, Livingstone J et al (2019) Molecular hallmarks of multiparametric magnetic resonance imaging visibility in prostate cancer. Eur Urol 76:18–23. https://doi.org/10.1016/j.eururo.2018.12.036